Mangiferin ameliorates colitis by inhibiting IRAK1 phosphorylation in NF-κB and MAPK pathways
Abstract
Mangiferin, a main constituent of the root of Anemarrhena asphodeloides and the leaves of Mangifera indica, inhibits NF-κB activation in macrophages. Therefore, we investigated effect of mangiferin on 2,3,4-trinitrobenzene sulfonic acid (TNBS)-induced colitis in mice and its anti-inflammatory mechanism in lipolysaccharide (LPS)- or peptidoglycan-stimulated mouse peritoneal macrophages. Mangiferin inhibited phosphorylation of nuclear factor-kappaB (NF-κB), interleukin-1 receptor-associated kinase 1 (IRAK1), and mitogen-activated protein kinases (MAPK) in peptidoglycan- or LPS-stimulated peritoneal macrophages. Mangiferin in the presence of SN50 inhibited LPS-stimulated NF-κB activation more potently than mangiferin alone. Mangiferin inhibited interaction of fluorescent p-IRAK1 antibody to LPS-stimulated peritoneal macrophages, but increased binding of fluorescent IRAK1 antibody. Mangiferin did not influence interaction of fluorescent LPS to toll-like receptor-4 on the macrophages. Molecular peak of mangiferin bound to IRAK1 was detected in the macrophages by mass analysis. Mangiferin (10 μM) inhibited LPS-stimulated expression of TNF-α, IL-1β and IL-6 by 81.0%, 89.5% and 88.3%, respectively, whereas it increased IL-10 expression by 131.8% compared to LPS-nontreated group. Mangiferin furthermore inhibited colon shortening, macroscopic score, and colonic myeloperoxidase activity in TNBS-induced colitic mice. Mangiferin inhibited TNBS-induced IRAK1 phosphorylation and NF-κB activ…
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
MGF exerts protective effects across a broad spectrum of pathological conditions, including inflammatory, neurodegenerative, ocular, renal, cardiovascular, dermatological and infectious diseases.
“In addition to its well-characterized roles in diabetes and cancer, MGF exerts protective effects across a broad spectrum of pathological conditions. These include inflammatory, neurodegenerative, ocular, renal, cardiovascular, dermatological and infectious diseases (7,36,106,115-118).”
From Mangiferin in human disease: Multifaceted mechanisms and applications (Review) (2026) · cites this paper as [106]
MGF activates splenocytes, facilitates plant lectin agglutination and stimulates NK-resistant tumor cell killing by macrophages.
“MGF activates splenocytes, facilitates plant lectin agglutination and stimulates NK-resistant tumor cell killing by macrophages (105,106).”
From Mangiferin in human disease: Multifaceted mechanisms and applications (Review) (2026) · cites this paper as [106]
In murine models, low concentrations of MGF (5-40 mg/ml) enhance the proliferation of splenocytes and thymocytes, whereas higher doses inhibit tumor cell proliferation.
“Dose-dependent immunostimulatory effects have also been observed in murine models; low concentrations (5-40 mg/ml) enhance the proliferation of splenocytes and thymocytes, whereas higher doses inhibit tumor cell proliferation.”
From Mangiferin in human disease: Multifaceted mechanisms and applications (Review) (2026) · cites this paper as [106]
Cites
Good cop, bad cop: the different faces of NF-κB
Perkins, N. D., & Gilmore, T. D. (2006) · Cell Death & Differentiation · doi:10.1038/sj.cdd.4401838 · Cited by 489 · see citing works
Flagged first, then by citations
Cited by
Sorted by citations
Mangiferin: A natural miracle bioactive compound against lifestyle related disorders
Imran, M., Arshad, M. S., Butt, M. S., Kwon, J.-H., Arshad, M. U., & Sultan, M. T. (2017) · Lipids in Health and Disease · doi:10.1186/s12944-017-0449-y · Cited by 366 · see citing works
Mangiferin: A xanthonoid with multipotent anti‐inflammatory potential
Saha, S., Sadhukhan, P., & Sil, P. C. (2016) · BioFactors · doi:10.1002/biof.1292 · Cited by 159 · see citing works
Mangiferin and Cancer: Mechanisms of Action
Gold-Smith, F., Fernandez, A., & Bishop, K. (2016) · Nutrients · doi:10.3390/nu8070396 · Cited by 158 · see citing works
Pattnaik, M., Pandey, P., Martin, G. J. O., Mishra, H. N., & Ashokkumar, M. (2021) · Foods · doi:10.3390/foods10020279 · Cited by 146 · see citing works
Morozkina, S. N., Nhung Vu, T. H., Generalova, Y. E., Snetkov, P. P., & Uspenskaya, M. V. (2021) · Biomolecules · doi:10.3390/biom11010079 · Cited by 82 · see citing works
Sarfraz, M., Khan, A., Batiha, G. E.-S., Akhtar, M. F., Saleem, A., Ajiboye, B. O., Kamal, M., Ali, A., Alotaibi, N. M., Aaghaz, S., et al. (2023) · Cancers · doi:10.3390/cancers15164194 · Cited by 20 · see citing works
Mangiferin in human disease: Multifaceted mechanisms and applications (Review)
Dai, Y., Huang, Q., Tan, M., Wang, Z., Jiang, C., Liu, Z., Zhang, S., & Song, S. (2026) · International Journal of Molecular Medicine · doi:10.3892/ijmm.2026.5736 · Cited by 3 · see citing works
“These include inflam‑ matory, neurodegenerative, ocular, renal, cardiovascular, dermatological and infectious diseases (7,36,106,115‑118).”
- Authors
- Jeong, J.-J., Jang, S.-E., Hyam, S. R., Han, M. J., & Kim, D.-H.
- Affiliations
- Kyung Hee University (KR)
- Corresponding author
- Kim, Dong-Hyun
- Venue
- European Journal of Pharmacology
- Publisher
- Elsevier BV
- Published
- 2014-10
- Volume
- 740
- Pages
- 652-661
- ISSN
- 0014-2999 (ISSN-L)
- OpenAlex
- W2038906350
- Cited by
- 78
- References
- 1
- Citations by year
- 2026: 9 · 2025: 6 · 2024: 5 · 2023: 4 · 2022: 5 · 2021: 7 · 2020: 6 · 2019: 7 · 2018: 4 · 2017: 10 · 2016: 10 · 2015: 4 · 2014: 1
- FWCI
- 17.93
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- Locations
- European Journal of Pharmacology (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Korea Health Industry Development Institute
- Ministry of Health and Welfare (HI14C1020)
- Topics
- Health Sciences › Medicine › Complementary and alternative medicine › Mangiferin and Mango Extracts
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Inflammatory Bowel Disease
- Health Sciences › Medicine › Complementary and alternative medicine › Natural Compounds in Disease Treatment
- Keywords
- mangiferin, colitis, NF-κB signaling, MAPK signaling, TNBS-induced colitis, peritoneal macrophages, lipopolysaccharide, peptidoglycan, anti-inflammatory activity, cyclooxygenase-2, inducible nitric oxide synthase, TNF-α, IL-1β, interleukin-6, IL-10, TLR4, Anemarrhena asphodeloides, mango
- MeSH terms
- Animals, Anti-Inflammatory Agents, Colitis, Lipopolysaccharides, Male, Mice, Inbred C57BL, Peptidoglycan, Phosphorylation, Trinitrobenzenesulfonic Acid, Cytokines, NF-kappa B, Macrophages, Peritoneal, Mitogen-Activated Protein Kinases, Xanthones, Interleukin-1 Receptor-Associated Kinases
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review